Sirnaomics H1 FY26 loss narrows to US$379,000; revenue remains no revenue

• Sirnaomics posted a net loss of US$379,000, narrowing from US$3.39 million a year earlier.
• Other gains rose to US$4.65 million, driven by a US$6 million gain on termination of lease.
• R&D expense fell 33% to US$2.03 million; administrative costs dropped 16% to US$2.15 million on lower staff costs.
• Cash and cash equivalents declined to US$7.19 million from US$13.52 million at Dec. 31, 2025; operating cash outflow was US$4.79 million.
• Pipeline focus sharpened around STP705, with FDA alignment completed for isSCC Phase IIb/III pivotal designs; STP122G Phase I finished with positive safety data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12305650), on August 28, 2026, and is solely responsible for the information contained therein.